Mycobacterium leprae Actively Modulates the Cytokine Response in Naïve Human Monocytes

ABSTRACT Leprosy is a chronic but treatable infectious disease caused by the intracellular pathogen Mycobacterium leprae. Host immunity to M. leprae determines the diversity of clinical manifestations seen in patients, from tuberculoid leprosy with robust production of Th1-type cytokines to lepromatous disease, characterized by elevated levels of Th2-type cytokines and a suboptimal proinflammatory response. Previous reports have indicated that M. leprae is a poor activator of macrophages and dendritic cells in vitro. To understand whether M. leprae fails to elicit an optimal Th1 immune response or actively interferes with its induction, we have examined the early interactions between M. leprae and monocytes from healthy human donors. We found that, in naïve monocytes, M. leprae induced high levels of the negative regulatory molecules MCP-1 and interleukin-1 (IL-1) receptor antagonist (IL-1Ra), while suppressing IL-6 production through phosphoinositide-3 kinase (PI3K)-dependent mechanisms. In addition, low levels of proinflammatory cytokines were observed in association with reduced activation of nuclear factor-κB (NF-κB) and delayed activation of IL-1β-converting enzyme, ICE (caspase-1), in monocytes stimulated with M. leprae compared with Mycobacterium bovis BCG stimulation. Interestingly, although in itself a weak stimulator of cytokines, M. leprae primed the cells for increased production of tumor necrosis factor alpha and IL-10 in response to a strongly inducing secondary stimulus. Taken together, our results suggest that M. leprae plays an active role to control the release of cytokines from monocytes by providing both positive and negative regulatory signals via multiple signaling pathways involving PI3K, NF-κB, and caspase-1.

[1]  A. Aderem,et al.  Polymorphisms in Toll-like receptor 4 (TLR4) are associated with protection against leprosy , 2009, European Journal of Clinical Microbiology & Infectious Diseases.

[2]  B. Foxwell,et al.  Mycolactone Inhibits Monocyte Cytokine Production by a Posttranscriptional Mechanism1 , 2009, The Journal of Immunology.

[3]  G. Kaplan,et al.  Exposure of Cord Blood to Mycobacterium bovis BCG Induces an Innate Response but Not a T-Cell Cytokine Response , 2008, Clinical and Vaccine Immunology.

[4]  R. I. López-Roa,et al.  The 3'UTR 1188 A/C polymorphism in the interleukin-12p40 gene (IL-12B) is associated with lepromatous leprosy in the west of Mexico. , 2008, Immunology letters.

[5]  Richard D. Wells,et al.  Human TLR1 Deficiency Is Associated with Impaired Mycobacterial Signaling and Protection from Leprosy Reversal Reaction , 2008, PLoS neglected tropical diseases.

[6]  L. Zhao,et al.  Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. , 2008, The Journal of infectious diseases.

[7]  J. Farrar,et al.  A common human TLR1 polymorphism regulates the innate immune response to lipopeptides , 2007, European journal of immunology.

[8]  R. Tapping,et al.  Cutting Edge: A Common Polymorphism Impairs Cell Surface Trafficking and Functional Responses of TLR1 but Protects against Leprosy1 , 2007, The Journal of Immunology.

[9]  Angelo Martino,et al.  Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone , 2007, The Journal of experimental medicine.

[10]  J. Cuevas,et al.  Erythema nodosum leprosum: reactional leprosy. , 2007, Seminars in cutaneous medicine and surgery.

[11]  G. Kaplan,et al.  Mycobacterium leprae Inhibits Dendritic Cell Activation and Maturation1 , 2007, The Journal of Immunology.

[12]  J. Dayer,et al.  Opposite Regulation of IL-1β and Secreted IL-1 Receptor Antagonist Production by Phosphatidylinositide-3 Kinases in Human Monocytes Activated by Lipopolysaccharides or Contact with T Cells1 , 2007, The Journal of Immunology.

[13]  Diana J L Williams,et al.  The Continuing Challenges of Leprosy , 2006, Clinical Microbiology Reviews.

[14]  M. Selman,et al.  A functional promoter polymorphism in monocyte chemoattractant protein–1 is associated with increased susceptibility to pulmonary tuberculosis , 2005, The Journal of experimental medicine.

[15]  S. Matsushita,et al.  Polymorphism of the 5′ flanking region of the IL-12 receptor β2 gene partially determines the clinical types of leprosy through impaired transcriptional activity , 2005, Journal of Clinical Pathology.

[16]  R. Lahiri,et al.  Effects of purification and fluorescent staining on viability of Mycobacterium leprae. , 2005, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[17]  M. Reed,et al.  Differential Monocyte Activation Underlies Strain-Specific Mycobacterium tuberculosis Pathogenesis , 2004, Infection and Immunity.

[18]  Masahiro Yamamura,et al.  Use of Genetic Profiling in Leprosy to Discriminate Clinical Forms of the Disease , 2003, Science.

[19]  P. Méndez-Samperio,et al.  Infection of human monocytes with Mycobacterium bovis BCG induces production of CC-chemokines. , 2003, The Journal of infection.

[20]  S. Akira,et al.  Activation and regulation of Toll-like receptors 2 and 1 in human leprosy , 2003, Nature Medicine.

[21]  A. Aderem,et al.  Cutting Edge: A Toll-Like Receptor 2 Polymorphism That Is Associated with Lepromatous Leprosy Is Unable to Mediate Mycobacterial Signaling1 , 2003, The Journal of Immunology.

[22]  T. Ottenhoff,et al.  Role of Tumor Necrosis Factor–α and Interleukin-10 Promoter Gene Polymorphisms in Leprosy , 2002 .

[23]  Koichi Suzuki,et al.  Mycobacterium leprae Infection in Monocyte-Derived Dendritic Cells and Its Influence on Antigen-Presenting Function , 2002, Infection and Immunity.

[24]  R. Charlab,et al.  Mycobacterium bovis BCG but not Mycobacterium leprae induces TNF-alpha secretion in human monocytic THP-1 cells. , 2001, Memorias do Instituto Oswaldo Cruz.

[25]  G. Kaplan,et al.  Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Mineo,et al.  Production of transforming growth factor‐beta 1 (TGF‐β1) by blood monocytes from patients with different clinical forms of leprosy , 2000, Clinical and experimental immunology.

[27]  D. Cosman,et al.  LIRs/ILTs/MIRs, inhibitory and stimulatory Ig-superfamily receptors expressed in myeloid and lymphoid cells. , 2000, Cytokine & growth factor reviews.

[28]  H. Dockrell,et al.  Monocyte-derived macrophage cytokine responses induced by M. bovis BCG. , 2000, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[29]  J. Battista,et al.  Inhibition of metabolism and growth of Mycobacterium leprae by gamma irradiation. , 2000, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[30]  B. Foxwell,et al.  The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. , 1999, Journal of immunology.

[31]  D. Kwiatkowski,et al.  Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. , 1997, The Journal of infectious diseases.

[32]  N. D. Mar,et al.  IL-15, an immunomodulator of T cell responses in intracellular infection. , 1997, Journal of immunology.

[33]  R L Modlin,et al.  Th1-Th2 paradigm: insights from leprosy. , 1994, The Journal of investigative dermatology.

[34]  H. Hayashi,et al.  Differential production of interleukin 1 (IL-1), IL-6, tumor necrosis factor, and IL-1 receptor antagonist by human monocytes stimulated with Mycobacterium leprae and M. bovis BCG. , 1993, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[35]  K. Smith,et al.  Recognition and destruction of Bacillus Calmette-Guerin-infected human monocytes , 1993, Journal of Experimental Medicine.

[36]  G. Kaplan,et al.  Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients , 1992, The Journal of experimental medicine.

[37]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor , 1990, Nature.

[38]  V. Sehgal,et al.  Immunology of Reactions in Leprosy , 1988, International journal of dermatology.

[39]  A. Mustafa,et al.  Reversal by Interleukin‐2 of the T Cell Unresponsiveness of Lepromatous Leprosy to Mycobacterium Leprae , 1984, Immunological reviews.

[40]  J. Convit,et al.  Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid , 1984, Nature.

[41]  B. Bloom,et al.  Lepromin-induced suppressor cells in patients with leprosy. , 1979, Journal of immunology.

[42]  Ridley Ds,et al.  Classification of leprosy according to immunity. A five-group system. , 1966 .

[43]  T. Ottenhoff,et al.  Role of tumor necrosis factor-alpha and interleukin-10 promoter gene polymorphisms in leprosy. , 2002, The Journal of infectious diseases.

[44]  K. Weinberg,et al.  Defining protective responses to pathogens: cytokine profiles in leprosy lesions. , 1991, Science.

[45]  D. H. McRae,et al.  A method for counting acid-fast bacteria. , 1968, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[46]  D. Ridley,et al.  Classification of leprosy according to immunity. A five-group system. , 1966, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.